Related references
Note: Only part of the references are listed.Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
Paul D. Miller et al.
BONE (2008)
The British Society for Rheumatology biologics register: 6 years on
K. L. Hyrich et al.
RHEUMATOLOGY (2008)
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy -: Results from the British Society for Rheumatology Biologics Register
W. G. Dixon et al.
ARTHRITIS AND RHEUMATISM (2007)
Interleukin 6: from bench to bedside
Norihiro Nishimoto et al.
NATURE CLINICAL PRACTICE RHEUMATOLOGY (2006)
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
R. N. Maini et al.
ARTHRITIS AND RHEUMATISM (2006)
Swedish registers to examine drug safety and clinical issues in RA
J Askling et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
L Klareskog et al.
LANCET (2004)
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
JCW Edwards et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis
AH Gerards et al.
RHEUMATOLOGY (2003)
Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
ME Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2003)